Pliant Therapeutics price target raised to $55 from $54 at H.C. Wainwright

H.C. Wainwright analyst Ed Arce raised the firm’s price target on Pliant Therapeutics to $55 from $54 and keeps a Buy rating on the shares. The analyst says data over the weekend strengthened bexotegrast’s case as the leading idiopathic pulmonary fibrosis agent in development. The drug’s safety and tolerability profile engenders confidence and "represents a major point of differentiation," the analyst tells investors in a research note.